Rethinking Diabetes: A Weekly Review
Malattie Metaboliche e Diabetologia
Emerging Therapies in Diabetes and Endocrine Disorders
This week we explore emerging therapies for PCOS, diabetes, and endocrine disorders, covering inositols, tirzepatide, finerenone combinations, and special considerations in pregnancy and cognitive impacts of diabetes.
Bibliography
1. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Authors: Greff D, Juhász AE, Váncsa S, et al.
Journal: Reproductive biology and endocrinology : RB&E, 2023 Jan 26
PMID: 36703143
DOI: 10.1186/s12958-023-01055-z
2. Management of Chronic Hypoparathyroidism and Hyperparathyroidism in Pregnancy/Lactation.
Authors: Pilz S, Kraus DA, Schmitt L, et al.
Journal: Current osteoporosis reports, 2026 Aug 1
PMID: 42541620
DOI: 10.1007/s11914-026-00979-w
3. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
Authors: Karagiannis T, Avgerinos I, Liakos A, et al.
Journal: Diabetologia, 2022 Aug
PMID: 35579691
DOI: 10.1007/s00125-022-05715-4
4. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.
Authors: Agarwal R, Joseph A, Anker SD, et al.
Journal: Journal of the American Society of Nephrology : JASN, 2022 Jan
PMID: 34732509
DOI: 10.1681/ASN.2021070942
5. Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis.
Authors: Sun J, Fan Z, Kou M, et al.
Journal: Frontiers in public health, 2025
PMID: 40860544
DOI: 10.3389/fpubh.2025.1622988
6. Type 1 Diabetes Mellitus and Cognitive Impairments: A Systematic Review.
Authors: Li W, Huang E, Gao S
Journal: Journal of Alzheimer's disease : JAD, 2017
PMID: 28222533
DOI: 10.3233/JAD-161250
7. Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome.
Authors: Tsimikas S, Szarek M, Cobbaert CM, et al.
Journal: Circulation, 2025 Dec 16
PMID: 41321238
DOI: 10.1161/CIRCULATIONAHA.125.073855
8. COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.
Authors: Agarwal R, Green JB, Heerspink HJL, et al.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2025 Aug 1
PMID: 39916475
DOI: 10.1093/ndt/gfaf022
9. Analysis of androgen modulation by natural products.
Authors: Sharma K, Yakubu J, Pandey AV
Journal: Pharmacological research, 2026 Sep
PMID: 42575271
DOI: 10.1016/j.phrs.2026.108377
Authors: Greff D, Juhász AE, Váncsa S, et al.
Journal: Reproductive biology and endocrinology : RB&E, 2023 Jan 26
PMID: 36703143
DOI: 10.1186/s12958-023-01055-z
2. Management of Chronic Hypoparathyroidism and Hyperparathyroidism in Pregnancy/Lactation.
Authors: Pilz S, Kraus DA, Schmitt L, et al.
Journal: Current osteoporosis reports, 2026 Aug 1
PMID: 42541620
DOI: 10.1007/s11914-026-00979-w
3. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
Authors: Karagiannis T, Avgerinos I, Liakos A, et al.
Journal: Diabetologia, 2022 Aug
PMID: 35579691
DOI: 10.1007/s00125-022-05715-4
4. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.
Authors: Agarwal R, Joseph A, Anker SD, et al.
Journal: Journal of the American Society of Nephrology : JASN, 2022 Jan
PMID: 34732509
DOI: 10.1681/ASN.2021070942
5. Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis.
Authors: Sun J, Fan Z, Kou M, et al.
Journal: Frontiers in public health, 2025
PMID: 40860544
DOI: 10.3389/fpubh.2025.1622988
6. Type 1 Diabetes Mellitus and Cognitive Impairments: A Systematic Review.
Authors: Li W, Huang E, Gao S
Journal: Journal of Alzheimer's disease : JAD, 2017
PMID: 28222533
DOI: 10.3233/JAD-161250
7. Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome.
Authors: Tsimikas S, Szarek M, Cobbaert CM, et al.
Journal: Circulation, 2025 Dec 16
PMID: 41321238
DOI: 10.1161/CIRCULATIONAHA.125.073855
8. COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.
Authors: Agarwal R, Green JB, Heerspink HJL, et al.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2025 Aug 1
PMID: 39916475
DOI: 10.1093/ndt/gfaf022
9. Analysis of androgen modulation by natural products.
Authors: Sharma K, Yakubu J, Pandey AV
Journal: Pharmacological research, 2026 Sep
PMID: 42575271
DOI: 10.1016/j.phrs.2026.108377
